Skip to main content
Premium Trial:

Request an Annual Quote

InteRNA, Radboud University Collaborate on miRNA Rx for Prostate Cancer

Premium

InteRNA Technologies and Radboud University Nijmegen Medical Centre said this week that they have agreed to collaborate on the development of microRNA-based therapeutics for prostate cancer.

Under the research arrangement, InteRNA's lentiviral-based miRNA over-expression library "will be applied in multi-parametric, high-throughput functional screening assays to identify the biological role of individual miRNAs and novel therapeutic targets in prostate cancer," the partners said.

Additional terms were not disclosed.

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.